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ABSTRACT  
Background. Few studies describe oral anticoagulant (OAC) prescription practices in very elderly 
patients with atrial fibrillation (AF).  
Methods. In this sub-analysis of the PREFER in AF study, performed in 2012, patients were stratified 
according to age (<80 [n = 5,575] and ≥80 years [n = 1,660]) and OAC treatment. Factors associated with 
OAC prescription were analyzed in a multivariate logistic regression model with backward elimination of 
variables least associated with OAC use. 
Results. Patients ≥80 years presented with permanent AF more often (p<0.0001) and reported fatigue and 
dyspnea more frequently (p<0.0001) and palpitations less frequently (p<0.0001) than patients <80 years. 
Hypertension, stroke, heart failure, coronary heart disease, peripheral arterial disease, cancer, chronic 
kidney disease, and prior major bleeding were significantly more frequent in ≥80 years. Most patients 
were treated with OACs in both age groups. The overall use of vitamin K antagonists was similar in both 
groups (78.2% vs.78.2% p=0.98), while the use of non-vitamin K antagonist OACs was lower in the ≥80 
years old group than in the <80 years group (4.5% vs. 6.6% p=0.001). Among patients ≥80 years, prior 
stroke and heart failure were significantly associated with OAC use, whereas higher age, prior bleeding, 
paroxysmal AF, chronic hepatic disease, and difficulties with self-care were associated with no OAC use.  
Conclusions. The current use of OAC in European AF patients was satisfactorily high in octogenarians, 
suggesting reasonable implementation of current guidelines. Interestingly, patients with poor quality of 
life were less often anticoagulated. This may warrant further studies. 
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Introduction 
Until a few years ago, only 50-60% of eligible patients with atrial fibrillation (AF) received anticoagulant 
treatments that were recommended to reduce the risk of stroke[1-6]. More recently, observational studies 
have shown that the percentage of AF patients treated with anticoagulant drugs has increased [7,8]. This 
trend suggests that physicians’ practices have been likely influenced by the endorsement of the 
CHA2DS2-VASc score for the assessment of the risk of stroke[9] and by the AF guidelines by the 
European Society of Cardiology (ESC) [10,11]. 
Very elderly (≥ 80 years of age) patients constitute a specific population. Since the incidence of AF-
related stroke rate increases with age[12-14], oral anticoagulant (OAC) treatment is particularly effective 
in the very elderly [15]. However, because very elderly patients are often frail and at higher risk of 
bleeding, the decision to treat them with an OAC is often more affected by the concern about bleeding 
than by the appraisal of the therapeutic benefits of anticoagulation [16-20]. Few data describe recent 
antithrombotic prescription practices in this specific population [7,21]. 
We performed a subanalysis of the large, cross-sectional, community-based Prevention of 
Thromboembolic events – European Registry in Atrial Fibrillation (PREFER in AF) study [8,22,23] to 
determine frequency and modalities of OAC prescription in AF patients older than 80 compared with 
younger patients. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
Methods 
This study is a subanalysis analysis of the PREFER in AF (Prevention of thromboembolic events – 
European Registry in Atrial Fibrillation) data set. Methodology of the study has previously been 
published [8]. In short, PREFER in AF registry was designed as a prospective observational study aiming 
at describing the characteristics and management of patients with AF with a particular focus on 
prevention of thromboembolic events. Inclusion criteria were age ≥ 18 years old and history of 
documented AF within the preceding 12 months. There were no explicit exclusion criteria. Furthermore, 
consecutive patients were included at each site in order to reduce selection bias. All data were entered into 
the European Registry for Atrial Fibrillation using electronic case report forms. Baseline data were 
collected from patients seen between January 2012 to January 2013 in seven representative European 
countries (Austria, France, Germany, Italy, Spain, Switzerland, and the UK). In addition to data on socio-
demographics, medical history and therapies, quality of life was also measured using the EQ-5D, a 
validated standardized non-disease-specific instrument for describing and appraising health-related 
quality of life and generate a cardinal index of health. It evaluates 5-domains mobility (walking), self-care 
(washing and dressing), usual activities, pain/discomfort, and anxiety/depression [24].It is one of the most 
widely used questionnaires in research settings. The overall rate of response was 80% in the the study. 
For the purpose of this subanalysis, patients were stratified according to their age at baseline (< 80 and 
≥ 80 years). Data were then further stratified according to treatment with an OAC. OAC treatment was 
defined as treatment with vitamin K antagonist (VKA) or non-vitamin K antagonist oral anticoagulant 
(NOAC) and no OAC treatment was defined as neither NOAC nor VKA use. CHADS2, CHA2DS2-VASC 
and HAS-BLED scores were calculated for each participant; however, because of missing values, they 
were only available for 91.1%, 91.2%, and 81.7% of participants over 80, respectively. 
Statistical analysis was performed using SAS
®
 9.2 (SAS Institute Inc., Cary, North Carolina, USA). 
Continuous variables are presented as means and standard deviation (SD). Categorical variables are 
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presented as numbers and percentages. Percentages were calculated after the number of patients with 
missing data was subtracted from the denominator. Patient characteristics at baseline were compared 
according to age groups and then according to OAC use. Between-group comparisons were performed 
using Chi-Squared tests for categorical variables and Wilcoxon or Kruskall Wallis tests for continuous 
variables. Rates of OAC use was graphed by country (combing Austria, Switzerland and Germany into a 
single region) and compared according to the age groups at baseline. We studied factors associated with 
OAC use in 2 different sets of logistic regression models, one for participants < 80 and one for 
participants ≥ 80 years. Covariates associated with OAC use in univariate models (p < 0.15) were entered 
in the multivariate models; then, through a backward elimination process, only variables associated with 
OAC use in the multivariate models were finally presented using Forrest plots.  
PREFER in AF study comprised 7,243 subjects, 7,225 patients were included for this analysis (18 
subjects were missing), 5,565 < 80 years old (77%) and 1,660 (23%) ≥ 80 years old. 
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Results 
Characteristics of the study population according to the age group 
Comparison between the 2 age groups upon baseline patient characteristics is shown in table 1. 
Octogenarian patients were more often female. Rates of hypertension, previous stroke, heart failure, 
coronary heart disease, peripheral arterial disease, cancer, renal failure, bleeding history, valvular diseases 
were significantly higher in the ≥ 80-year than in the < 80-year group. Rate of dilated left atrial was 
higher in the ≥ 80-year group. Left ventricular ejection fraction was lower in the ≥ 80-year group. As a 
consequence of older age and these distributions, CHADS2, CHA2DS2-VASC, and HAS-BLED were 
higher in the ≥ 80 year than in the < 80 year group (table 2).  
In addition, octogenarians had more often permanent AF (51% vs. 35%, p<.0001) and reported more 
frequently AF-related symptoms such as fatigue and dyspnea and less frequently palpitations (table 2).  
Responses to the EQ-5D health questionnaire (figure 1) showed that for all 5 domains patients in the ≥ 80 
year group had more often problems with mobility, self-care, usual activities and pain/discomfort or 
anxiety/depression than patients in the < 80 year group (p < 0.0001 for all 5 domains). 
Table 3 compares the 2 age-groups upon pharmacological and non-pharmacological strategies. The 
overall use of OACs was high in the whole population (82.6%), with no statistically significant difference 
between the two age groups. The frequency of use of VKAs was similar the two groups (78.2% vs.78.2% 
p=0.98), while NOACs were less frequently prescribed in the ≥ 80 year group (4.5% vs. 6.6% p=0.001). 
Antiplatelet was overall used in 24.8% in < 80 year old and 25.4% in ≥ 80 year old patients (p=0.63).  
Antiplatelet was associated with OACs in 13.7% (13.9% in < 80 year old and 13.0% in ≥ 80 year old 
patient, p=0.30). Rhythm control therapy was less frequently used in older subjects (53.2% vs. 62.0%, 
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p < 0.0001). Amiodarone, dronedarone, flecainide and propafenone were less prescribed in ≥ 80 year old 
patients than in < 80 year old patients  
When OAC prescriptions were stratified by country (figure 2), OAC prescription rates were high across 
all the countries with some variations from country to country. The lowest rate of OAC prescription was 
observed in the whole population and in octogenarian patients (71.7% and 68.1%, respectively) in Italy. 
Conversely the highest rate of OAC prescription was observed in the whole population (90.5%) in France. 
In the German region the highest rate was observed in octogenarian patients (89.0%). France was also the 
only country with a significant difference in OAC prescription between age-groups (< 80 yo, 91.6% vs. 
≥ 80 yo, 88.2%, p < 0.05). 
Factors associated with oral anticoagulant use according to age 
Subjects ≥ 80 years old 
In univariate analysis (supplementary table), among patients ≥ 80 years old, factors significantly 
associated with OAC use were prior ischemic stroke, heart failure and higher BMI, SBP and DBP. 
Factors significantly associated with OAC non-use were older age, paroxysmal and persistent AF, history 
of bleeding and chronic hepatic diseases. In the OAC use group compared to nonuse of-OAC, mean 
CHADS2 and CHA2DS2-VASC score were higher (2.8 (1.2) vs. 2.5 (1.0), p=0.002 and 4.7 (1.4) vs. 4.4 
(1.3), p=0.04 respectively) and HAS-BLED score was lower (2.4 (1.0) vs. 2.7 (0.9), p<0.0001). Results of 
the EQ-5D showed that factors significantly associated with no prescription of OACs were presence of 
problems for self-care and usual activities (figure 1).  
In the multivariate analysis, (figure 3a), OAC use was significantly higher with prior ischemic stroke and 
heart failure. Factors associated with no prescription of OACs were older age, prior bleeding, paroxysmal 
AF, chronic hepatic disease and difficulties with self-care. 
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Subjects < 80 years old 
In univariate analysis (supplementary table), among patients < 80 years old, factors significantly 
associated with OAC use were heart failure, prior stroke, coronary heart disease, hypertension, diabetes 
and COPD. Factors significantly associated with OAC non-use were paroxysmal AF and current 
smoking. In the OAC use group compared to nonuse of OAC, mean CHADS2 and CHA2DS2-VASC score 
were higher (1.8 (1.2) vs. 1.3 (1.2), p < 0.0001and 3.2 (1.6) vs. 2.4 (1.8), p < 0.0001 respectively). HAS-
BLED scores however were not significantly different between OAC subgroups (1.9 (1.1) vs. 1.9 (1.2), 
p=0.70). Results of the EQ-5D (see figure 1) showed use of OACs was significantly associated with 
mobility problem and pain/discomfort. 
In the multivariate analysis (figure 3b), OAC use was significantly higher with age, prior stroke, heart 
failure, systolic blood pressure, dyslipidemia and significantly lower with paroxysmal AF, current 
smoking and difficulties with self-care. 
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Discussion 
Analyzing data from an European multinational registry including 1660 participant 80 years and older, we 
found that the use of anticoagulant therapy was high in octogenarians and has increased compared to 
previous studies [3] suggesting that older age is a lesser issue for AC prescription and that current 
guideline are better implemented in this population. Compared with younger patients, octogenarian 
patients with AF had more comorbidities with higher CHA2DS2-VASC and HAS-BLED scores, and 
overall lower quality of life according to the EQ-5D health questionnaire. Patients in the ≥ 80 year group 
reported more frequently symptoms such as fatigue and dyspnea and less frequently palpitations and more 
frequently presented with a permanent AF. The percentage of use of VKAs was similar to that in younger 
patients while NOACs were less frequently prescribed to ≥ 80 patients.  
Our results confirm prior reports on characteristics of very old patients with AF. It is known that in older 
subjects AF is often either non-symptomatic or presenting with non-specific symptoms, hence being often 
an incidental finding [25]. In our study, only 13% of octogenarians described palpitations, which is in line 
with previous studies reporting that less than 10% of AF patients over the age of 80 years had 
palpitations [26]. This is why an annual pulse assessment is recommended to improve AF detection in the 
elderly [10] as shown by SAFE study [27]. Furthermore, according to guidelines elderly patients had 
more often permanent AF and rate control strategy was preferred in octogenarian patients [10]. 
Oral anticoagulant prescription rates were high in the seven European countries participating in the study 
with a mean of 82.6% of OAC prescription rate in octogenarian subjects, although some variation from 
country to country was noted. Italy had the lowest rate of OAC prescription and France the highest. This 
rate of OAC use is higher than previously reported [3]. Recent studies have shown an increased 
prevalence of anticoagulant use [2,8,21,28]. However few studies were specifically focused on very old 
population. PREFER-AF is one of the most recent cohorts that included one of the largest proportions of 
octogenarian populations. A recent report on a French cohort, the SAGES study, including 447 subjects 
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over 80 years old, showed a similar rate of OAC prescription, i.e. 75.6% [7]. These findings show a 
progression in prescription practices towards a greater adherence to current European guidelines [10,11]. 
Factors for long considered barriers to anticoagulant use in the elderly, such as frequent comorbidities, 
fear of bleeding and unawareness of guidelines [3] might have been overcome because of the increase of 
evidence for the benefit of anticoagulant therapy especially in the AF elderly population [29]. On the 
other hand, the specific setting, i.e., patients, mostly outpatients, referred to cardiologists, might also 
explain the very high frequency of OAC use compared with what shown in other settings, e.g., inpatients 
admitted to internal medicine or geriatric wards [30]. 
In particular, we found that, among anticoagulants, vitamin K antagonists were prescribed more often 
than NOAC, with no significant differences between age groups. The overall rate of NOAC use was low 
(6.2%), consistently with the previous studies [21], and NOAC particularly low in the very elderly 
(4.6%). These results are not entirely surprising as in 2012 when the study was conducted, NOACs were 
just starting to become available and physicians would have been expected to exercise caution when 
prescribing a newly approved drug to a high risk population. 
Analysis of determinant of OAC prescription showed some different factors between the 2 groups of age. 
Heart failure and stroke were associated with OAC use and paroxysmal AF and difficulty with self-care 
were associated with nonuse of OAC in both groups. In contrast history of bleeding and chronic hepatic 
disease were associated with nonuse of OAC only in the octogenarian group. Cardiovascular risk factors 
(dyslipidemia, SBP) were associated with OAC use only in < 80-year group. Interestingly, age had a 
different type of relationship with OAC use in the 2 age groups. It was associated with OAC use in < 80 
year group and associated with nonuse in ≥ 80-year group. CHADS2 and CHA2DS2-VASC scores were 
associated with OAC use in both age groups whereas HAS-BELD was only associated with nonuse of 
OAC in ≥ 80 year old group. These findings suggest that, despite the change in prescription frequency, 
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factors known to affect the patient risk of bleeding are still the main determinant of caution in OAC 
prescription.  
The lower prescription of OAC in paroxysmal AF has already been observed [7,31] and may be related to 
the uncertainty of the diagnosis or to the belief that paroxysmal AF is less severe and at lower cardio-
embolic risk than persistent/permanent AF.  
In our population 13.7% (13.9% in < 80 year old and 13.0% in ≥ 80 year old patient) took simultaneously 
antiplatelet and anticoagulant. In recent randomized controlled trials with oral anticoagulants (NOAC vs 
Warfarin), aspirin was used at baseline in 34% of participants [32]. In RE-LY study aspirin was used 
continuously during the treatment period in 21.1%, 19.6%, and 20.8% of patients receiving 110 mg of 
dabigatran, 150 mg of dabigatran and warfarin, respectively [33]. In our octogenarian population the 
frequency of the association oral anticoagulant with antiplatelet drugs was lower because of the increased 
risk of bleeding of this dual therapy after 80 years.  
Finally, OAC use in both younger patients and in the very elderly was significantly associated with 
difficulties with self-care. Similarly, in the S.AGES study, lower autonomy was significantly associated 
with nonuse of VKA in patients < 80 [7]. As quality of life variables are not currently included in 
formalized risk/benefit assessments, these data support the idea that, regardless of age, some level of 
subjectivity is still influencing physician decisions. In particular, the association of problems with self-
care and nonuse of OAC may reflect physician fears that patients would not be able to take medication 
consistently or adequately. Additional studies may be warranted in order to determine whether concerns 
about self-care impacting OAC use are justified. 
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Limitations 
Selection bias could have been occurred during site selection within each country. Patient-selection could 
also have been subject to bias despite the instruction that physicians should enroll consecutive patients. 
However, overall patient characteristics in the PREFER AF registry were similar to those described in 
other registries [8]. Finally, as previously stated, our study was conducted in a specific setting of care, 
excluding very frail patients, such as residents in nursing homes with multiple comorbidities and major 
functional disability. 
Strengths  
The PREFER in AF study is a large cohort designed to provide a picture of the management of AF in 
seven European countries. All design aspects have been established by the scientific committee and 
accomplished by an independent CRO except the selection of the countries. Within each country 
representative sites have been selected in order to enroll a representative patient population that provided 
real-life data. The study includes a large proportion of subjects ≥ 80 years old with AF and contained 
quality of life data that are usually not assessed in such observational studies. Lastly, few studies assessed 
quality of life and its relationship with OAC therapies. 
Conclusion 
These data confirm the change in treatment patterns in Europe in recent years and show that the use of 
OACs for AF treatment has been integrated in daily, community-based practices both in younger patients 
and in the very elderly. Particularly use of anticoagulant therapy was higher even after 80 years than in 
previous studies suggesting that recent international guidelines are better implemented in this specific 
population. Factors associated with use of OAC vary according to age (> or < 80 years). Quality of life 
appears to influence the OAC prescription although no data support this fact. Additional studies are thus 
needed to assess the impact of quality of life on stroke and bleeding risk.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
Acknowledgements 
We would like to thank Mostefa Bourkaib, MD and Hélène Dassule, PhD for their editorial help. 
JSV, PMM and MM report no relationships that could be construed as a conflict of interest. 
OH received consultant/advisory/lecture fees from Daiichi-Sankyo, Bayer, Boehringer-Ingelheim, 
BMS/Pfizer, Novartis, Servier, Astra-Zeneca. Sannofi. 
JULH received consultant/advisory/lecture fees from Daiichi-Sankyo, Merck, Lilly, Novartis, 
BMS/Pfizer, Bayer, Boehringer-Ingelheim, Meda, Sanofi, Astra-Zeneca, Correvio and Servier. 
JS and PL are employees of Daiichi-Sankyo Europe GmbH 
RDC consultant/advisory/lecture fees related to atrial fibrillation from Daiichi-Sankyo, Merck, Lilly, 
Novartis, BMS/Pfizer, Bayer and Boehringer-Ingelheim. 
PK received consulting fees/honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers 
Squibb, Daiichi-Sankyo, 3M Medica, MEDA Pharma, Medtronic, Merck, Otsuka, Pfizer, Sanofi-Aventis, 
Servier, Siemens and Takeda. 
 
 
JSV, OH, MM, PMM have made substantial contributions to the analysis and the interpretation of data, 
the drafting the article and approved of the version to be submitted. 
JS and PL have made substantial contributions to the analysis, revised the article critically and approval 
of the version to be submitted. 
RDC, JULH and PK have made substantial contributions to the analysis and the interpretation of data, 
revised the article critically and approved of the version to be submitted. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
Table 1, Patient characteristics according to age  
General characteristics. % (N) 
Total < 80 yo ≥ 80 yo 
p 
N=7225 N=5565 N=1660 
Age, M (SD) 71.5 (7.9) 67.8 (9.34) 83.7 (3.17) <.0001 
Male gender 60.0 (4336) 63.7 (3543) 47.8 (793) <.0001 
Education level     
   Primary school 47.9 (3461) 50.3 (2549) 60.4 (912) 
<.0001    Secondary school 29.4 (2122) 33.3 (1691) 28.6 (431) 
   High school diploma or above 13.8 (997) 16.4 (831) 11 (166) 
Body mass index (kg/m2), M (SD) 27.9 (4.9) 28.4 (5.08) 26.4 (4.27) <.0001 
Smoking status     
   Never 56.6 (4088) 57.7 (3017) 68.4 (1071) 
<.0001    Former 30.5 (2206) 33.3 (1744) 29.5 (462) 
  Current 6.93 (501) 9 (469) 2 (32) 
Previous stroke 8.48 (613) 7.8 (430) 11.1 (183) <.0001 
COPD 11.3 (815) 10.8 (593) 13.6 (222) 0.0020 
Arterial hypertension 72.5 (5239) 71.4 (3954) 78.3 (1285) <.0001 
Diabetes 22.4 (1616) 22.4 (1235) 23.1 (381) 0.51 
Dyslipidemia 43.4 (3133) 45.5 (2469) 40.7 (664) 0.0007 
Chronic heart failure 21.3 (1539) 19 (1045) 30.3 (494) <.0001 
Coronary heart disease 23.4 (1688) 22.2 (1214) 29.3 (474) <.0001 
Peripheral arterial disease 4.42 (319) 3.9 (215) 6.4 (104) <.0001 
Active cancer 3.22 (233) 2.9 (161) 4.4 (72) 0.003 
Chronic hepatic diseases 2.05 (148) 2.1 (115) 2 (33) 0.85 
History of thromboembolic events 2.49 (180) 2.4 (130) 3.1 (50) 0.11 
Bleeding history  7.22 (522) 6.6 (367) 9.5 (155) 0.0001 
SBP (mmHg), M (SD) 132 (17) 131.2 (16.4) 132.8 (17.3) 0.0007 
DBP (mmHg), M (SD) 77.6 (10.2) 78.1 (10.2) 75.9 (10.3) <.0001 
Renal function     
   eGFR ≥90 87.4 (6152) 90.2 (4896) 78.0 (1258) 
<.0001 
   eGFR 60-89 2.34 (169) 2.6 (142) 1.7 (27) 
   eGFR 30-59 8.30 (600) 6.2 (334) 16.5 (266) 
   eGFR 15-29 1.51 (109) 0.9 (50) 3.7 (59) 
   eGFR <15 0.12 (9) 0.1 (6) 0.2 (3) 
Ejection fraction %, M (SD) 56.5 (11.6) 56.7 (11.6) 55.9 (11.8) 0.008 
Dilated left atrial (>40mm) 58.6 (4233) 68.2 (3190) 76.9 (1043) <.0001 
Severe aortic stenosis 0.78 (56) 0.6 (31) 1.5 (25) 0.0001 
Severe mitral insufficiency 1.23 (89) 1.1 (61) 1.7 (28) 0.06 
Heart valve replacement 5.37 (388) 5.4 (296) 5.7 (92) <.0001 
% (N), percentage (number); yo, years old; M (SD), Mean (standard deviation), Comparisons between 
groups were performed using Chi-Squared tests for categorical variables and Wilcoxon or Kruskall Wallis 
tests for continuous variables. COPD, chronic obstructive pulmonary disease; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate in mL/min/1.73 m2 
according to MDRD formula. 
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Table 2, AF characteristics and risk scores according to age groups 
AF characteristics. % (N) 
Total < 80 yo ≥ 80 yo p 
value 7225 5565 1660 
Current AF type         
   Paroxysmal 29.9 (2160) 32.6 (1806) 21.5 (354) 
<.0001 
   Persistent 24.0 (1733) 25.5 (1412) 19.5 (321) 
   Long standing persistent 7.14 (516) 6.9 (384) 8 (132) 
   Permanent 38.6 (2786) 34.9 (1943) 51.1 (843) 
Current Heart rhythm     
   Sinus rhythm 31.2 (2251) 34.7 (1916) 20.3 (335) 
<.0001 
   Atrial fibrillation 64.4 (4652) 61.7 (3407) 75.6 (1245) 
   Atrial flutter 1.94 (140) 2 (111) 1.8 (29) 
   Other  1.73 (125) 1.6 (87) 2.3 (38) 
Palpitations     
   Never or occasional 79.5 (5741) 79 (4336) 86.5 (1405) 
<.0001 
   Intermediate or frequent 19.0 (1372) 21 (1153) 13.5 (219) 
Fatigue     
   Never or occasional 64.7 (4672) 68 (3708) 59.4 (964) 
<.0001 
   Intermediate or frequent 33.3 (2407) 32 (1747) 40.6 (660) 
Dyspnea     
   Never or occasional 67.5 (4875) 70.2 (3852) 62.6 (1023) 
<.0001 
   Intermediate or frequent 31.1 (2247) 29.8 (1636) 37.4 (611) 
Risk Scores, M (SD)     
   CHADS2 1.93 (1.22) 1.7 (1.23) 2.7 (1.18) <.0001 
   CHA2DS2VASc 3.37 (1.62) 3 (1.68) 4.6 (1.41) <.0001 
   HAS-BLED 2.04 (1.13) 1.9 (1.16) 2.5 (1.02) <.0001 
% (N), percentage (number); yo, years old; M (SD), Mean (standard deviation). 
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Table 3, Atrial fibrillation treatment according to age 
AF treatment, % (N) 
Total < 80 yo ≥ 80 yo 
P* 
7225 5565 1660 
Anticoagulants 82.6 (5967)  82.9 (4612) 81.6 (1355) 0.24 
   VKA (all)  78.2 (5651) 78.2 (4353) 78.2 (1298) 0.98 
       Warfarin 33.6 (2429) 34.3 (1908) 31.4 (521) 0.03 
       Phenprocoumon  18.3 (1320) 19.3 (1074) 14.6 (246) <.0001 
       Acenocoumarol  13.0 (939) 12.7 (706) 14 (233) 0.15 
       Fluindione 13.2 (957) 11.8 (654) 18.3 (303) <.0001 
   NOACs (all) 6.10 (441) 6.6 (367) 4.5 (74) 0.001 
       Dabigatran 4.04 (292) 4.4 (245) 2.8 (47) 0.004 
       Rivaroxaban 1.99 (144) 2.1 (117) 1.6 (27) 0.22 
       Apixaban 0.11 (8) 0.1 (8) 0 (0) 0.12 
Antiplatelets agents (all) 24.9 (1800) 24.8 (1379) 25.4 (421) 0.63 
   Aspirin 19.9 (1438) 20.1 (1121) 19.1 (317) 0.35 
   Clopidogrel 4.10 (296) 3.9 (219) 4.6 (77) 0.20 
   Others 0.91 (66) 0.7 (39) 1.6 (27) 0.0005 
APL as monotherapy 11.2 (809) 10.8 (603) 12.4 (206) 0.07 
VKA as monotherapy 66.5 (4805) 66.1 (3681) 67.6 (1122) 0.27 
No antithrombotic treatment 6.2 (450) 6.3 (350) 6.0 (99) 0.60 
Rhythm control therapy  60.0 (4336) 62.0 (3453) 53.2 (883) <.0001 
   Class I Flecainide 10.5 (762) 12.4 (691) 4.3 (71) <.0001 
   Class I Propafenone 2.91 (210) 3.3 (183) 1.6 (27) 0.0004 
   Class I Quinidine 0.18 (13) 0.2 (12) 0.1 (1) 0.19 
   Class III Amiodarone 24.2 (1751) 25.6 (1423) 19.8 (328) <.0001 
   Class III Dronedarone 4.03 (291) 4.6 (256) 2.1 (35) <.0001 
   Class III d,I-Sotalol 5.51 (398) 5.6 (310) 5.3 (88) 0.67 
   Other antiarrhythmic drugs 28.3 (2047) 28.2 (1572) 28.6 (475) 0.77 
Cardioversion     
   Electrical cardioversion† 18.1 (1302) 20.8 (1153) 9 (149) <.0001 
   Pharmacologic cardioversion* 19.5 (1401) 21.1 (1170) 14 (231) <.0001 
Catheter ablation* 5.18 (356) 6.3 (351) 0.3 (5) <.0001 
Pace maker or Defibrillator 9.03 (649) 8.1 (448) 12.3 (201) <.0001 
% (N), percentage (number); yo, years old; M (SD), * Comparisons between groups were performed 
using Chi-Squared tests for categorical variables and Wilcoxon/Kruskall Wallis tests for continuous 
variables; † in the past 12 months. AF, atrial fibrillation; APL, antiplatelet agent; VKA, vitamin K 
antagonist; NOAC, direct oral anticoagulant. 
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Figure legends 
Figure 1, Patient EQ-5D according to age and oral anticoagulant use 
Comparisons between groups with Chi-Squared tests; * p < 0.05; ** p < 0.01; *** p <0.001. 
OAC +, use of oral anticoagulant; OAC –, nonuse of oral anticoagulant. 
 
 
Figure 2, Treatment with oral anticoagulants according to age and country 
The term ‘Germany’ was used to describe data from Germany, Austria, and Switzerland.  
 
 
Figure 3a, Determinants of OACs use in < 80 year old subjects with atrial fibrillation. 
Figure 3b, Determinants of OACs use in ≥ 80 year old subjects with atrial fibrillation 
Logistic regression model with oral anticoagulant use as dependent variables and backward elimination of 
independent variables; * p < 0.05, ** p < 0.01, *** p < 0.001. 
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